The development of early monoclonal antibody (mAb) therapies centered around the hybridoma platform requires the production of target antigen or immunogen and animal immunizations. This means there ...

THE STRUCTURE AND FUNCTION OF RECOMBINANT HUMANIZED TYPE III COLLAGEN AS WELL AS ITS RELATED PRODUCT approved by CHINA NMPa for COSMETICS USE (ADAPTED FROM THE AUTHORS’ PUBLICATION IN Biochemical and ...

MELBOURNE, Australia--(BUSINESS WIRE)--Propanc Biopharma, Inc. (OTC Pink: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company developing novel cancer treatments for patients suffering from ...

Schlieren / Zurich, Switzerland, 9 February, 2026 – Memo Therapeutics AG (“MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral infections and ...

Recombinant antibody technology has addressed many problems associated with hybridoma-based platforms, opening the door to a new class of biologics. Today, this technology continues to contribute to ...

Quadrivalent recombinant influenza vaccines contain three times the amount of hemagglutinin protein as standard-dose egg-based vaccines, and the recombinant formulation is not susceptible to antigenic ...

Novel Delivery System for High-Molecular-Weight Collagen Advances Anti-Aging Science at the Society of Cosmetic Chemists' Annual Meeting In recent years, recombinant collagen has become a key ...

ACROBiosystem's SAFENSURE ™ Recombinant Factor C Endotoxin Detection Kit is a novel endotoxin detection kit powered by recombinant Factor C technology. Comparable to LAL method - The endpoint ...

The launch of AlbuFree™ DX underscores Dyadic’s strategy to prioritize recombinant protein products that have clear commercial pathways and are supported by well-established end markets. Under the ...

Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technology Agreement includes R&D funding for exploratory work, technology access and, assuming exercise of the option by ...